Vascular Biogenics Ltd. (VBLT) Sees Large Volume Increase
Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) saw unusually-high trading volume on Thursday . Approximately 1,163,139 shares traded hands during trading, an increase of 424% from the previous session’s volume of 221,803 shares.The stock last traded at $4.27 and had previously closed at $4.01.
VBLT has been the topic of a number of research reports. Roth Capital restated a “buy” rating and set a $22.00 price objective on shares of Vascular Biogenics in a research report on Thursday, June 9th. HC Wainwright started coverage on Vascular Biogenics in a research report on Tuesday, June 28th. They issued a “buy” rating and a $11.00 price target on the stock. Chardan Capital reiterated a “buy” rating on shares of Vascular Biogenics in a research report on Tuesday, June 7th. Zacks Investment Research lowered Vascular Biogenics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 11th. Finally, Piper Jaffray Cos. reiterated a “buy” rating and issued a $14.00 price target on shares of Vascular Biogenics in a research report on Tuesday, June 7th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Vascular Biogenics presently has a consensus rating of “Buy” and a consensus target price of $13.67.
The firm’s market cap is $100.07 million. The stock’s 50-day moving average price is $4.09 and its 200 day moving average price is $3.74.
Vascular Biogenics (NASDAQ:VBLT) last issued its quarterly earnings data on Monday, August 15th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.09. On average, analysts predict that Vascular Biogenics Ltd. will post ($0.64) earnings per share for the current fiscal year.
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.